{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:03:15Z","timestamp":1795042995257,"version":"4.10.2"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["HL080494"],"award-info":[{"award-number":["HL080494"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["HL084553"],"award-info":[{"award-number":["HL084553"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI142756"],"award-info":[{"award-number":["U01 AI142756"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["RM1 HG009490"],"award-info":[{"award-number":["RM1 HG009490"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["R35 GM118062"],"award-info":[{"award-number":["R35 GM118062"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["HL080494"],"award-info":[{"award-number":["HL080494"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["HL084553"],"award-info":[{"award-number":["HL084553"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005237","name":"Helen Hay Whitney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005237","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science Foundation Graduate Research Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dominant missense pathogenic variants in cardiac myosin heavy chain cause hypertrophic cardiomyopathy (HCM), a currently incurable disorder that increases risk for stroke, heart failure and sudden cardiac death. In this study, we assessed two different genetic therapies\u2014an adenine base editor (ABE8e) and a potent Cas9 nuclease delivered by AAV9\u2014to prevent disease in mice carrying the heterozygous HCM pathogenic variant myosin R403Q. One dose of dual-AAV9 vectors, each carrying one half of RNA-guided ABE8e, corrected the pathogenic variant in \u226570% of ventricular cardiomyocytes and maintained durable, normal cardiac structure and function. An additional dose provided more editing in the atria but also increased bystander editing. AAV9 delivery of RNA-guided Cas9 nuclease effectively inactivated the pathogenic allele, albeit with dose-dependent toxicities, necessitating a narrow therapeutic window to maintain health. These preclinical studies demonstrate considerable potential for single-dose genetic therapies to correct or silence pathogenic variants and prevent the development of HCM.<\/jats:p>","DOI":"10.1038\/s41591-022-02190-7","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T12:03:14Z","timestamp":1676548994000},"page":"412-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":207,"title":["Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice"],"prefix":"10.1038","volume":"29","author":[{"given":"Daniel","family":"Reichart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-6424","authenticated-orcid":false,"given":"Hiroko","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-4690","authenticated-orcid":false,"given":"Joshua M.","family":"Gorham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-7308","authenticated-orcid":false,"given":"Aditya","family":"Raguram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"DeLaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia D. C.","family":"Marsiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeev","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Chmatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-4695","authenticated-orcid":false,"given":"Nerea","family":"Zabaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-3566","authenticated-orcid":false,"given":"Jonathan G.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-1209","authenticated-orcid":false,"given":"Christine","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"2190_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","volume":"14","author":"AC Garfinkel","year":"2018","unstructured":"Garfinkel, A. C., Seidman, J. G. & Seidman, C. E. Genetic pathogenesis of hypertrophic and dilated cardiomyopathy. Heart Fail Clin. 14, 139\u2013146 (2018).","journal-title":"Heart Fail Clin."},{"key":"2190_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-genom-083118-015306","volume":"20","author":"R Yotti","year":"2019","unstructured":"Yotti, R., Seidman, C. E. & Seidman, J. G. Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies. Annu. Rev. Genomics Hum. Genet. 20, 129\u2013153 (2019).","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"2190_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/gim.2016.90","volume":"19","author":"R Walsh","year":"2017","unstructured":"Walsh, R. et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med. 19, 192\u2013203 (2017).","journal-title":"Genet. Med."},{"key":"2190_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho, C. Y. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138, 1387\u20131398 (2018).","journal-title":"Circulation"},{"key":"2190_CR5","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","volume":"105","author":"CY Ho","year":"2002","unstructured":"Ho, C. Y. et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105, 2992\u20132997 (2002).","journal-title":"Circulation"},{"key":"2190_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jcmg.2008.08.003","volume":"2","author":"M Michels","year":"2009","unstructured":"Michels, M. et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc. Imaging 2, 58\u201364 (2009).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"2190_CR7","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJM199112193252501","volume":"325","author":"A Rosenzweig","year":"1991","unstructured":"Rosenzweig, A. et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N. Engl. J. Med. 325, 1753\u20131760 (1991).","journal-title":"N. Engl. J. Med."},{"key":"2190_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265\u2013280 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"2190_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2190_CR10","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","volume":"185","author":"A Raguram","year":"2022","unstructured":"Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806\u20132827 (2022).","journal-title":"Cell"},{"key":"2190_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.272.5262.731","volume":"272","author":"AA Geisterfer-Lowrance","year":"1996","unstructured":"Geisterfer-Lowrance, A. A. et al. A mouse model of familial hypertrophic cardiomyopathy. Science 272, 731\u2013734 (1996).","journal-title":"Science"},{"key":"2190_CR12","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1172\/JCI42028","volume":"120","author":"P Teekakirikul","year":"2010","unstructured":"Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2. J. Clin. Invest. 120, 3520\u20133529 (2010).","journal-title":"J. Clin. Invest."},{"key":"2190_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1083\/jcb.107.2.573","volume":"107","author":"JH Mar","year":"1988","unstructured":"Mar, J. H., Antin, P. B., Cooper, T. A. & Ordahl, C. P. Analysis of the upstream regions governing expression of the chicken cardiac troponin T gene in embryonic cardiac and skeletal muscle cells. J. Cell Biol. 107, 573\u2013585 (1988).","journal-title":"J. Cell Biol."},{"key":"2190_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/science.1236921","volume":"342","author":"J Jiang","year":"2013","unstructured":"Jiang, J., Wakimoto, H., Seidman, J. G. & Seidman, C. E. Allele-specific silencing of mutant Myh6 allele in mice suppresses hypertrophic cardiomyopathy. Science 342, 111\u2013114 (2013).","journal-title":"Science"},{"key":"2190_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","volume":"589","author":"LW Koblan","year":"2021","unstructured":"Koblan, L. W. et al. In vivo base editing rescues Hutchinson\u2013Gilford progeria syndrome in mice. Nature 589, 608\u2013614 (2021).","journal-title":"Nature"},{"key":"2190_CR16","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1073\/pnas.0600012103","volume":"103","author":"R Varga","year":"2006","unstructured":"Varga, R. et al. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson\u2013Gilford progeria syndrome. Proc. Natl Acad. Sci. USA 103, 3250\u20133255 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2190_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"2190_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41587-020-0412-8","volume":"38","author":"SM Miller","year":"2020","unstructured":"Miller, S. M. et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat. Biotechnol. 38, 471\u2013481 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2190_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1126\/science.aas9129","volume":"361","author":"H Nishimasu","year":"2018","unstructured":"Nishimasu, H. et al. Engineered CRISPR\u2013Cas9 nuclease with expanded targeting space. Science 361, 1259\u20131262 (2018).","journal-title":"Science"},{"key":"2190_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883\u2013891 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2190_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617\u2013621 (2016).","journal-title":"Science"},{"key":"2190_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","volume":"107","author":"F Sedaghat-Hamedani","year":"2018","unstructured":"Sedaghat-Hamedani, F. et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin. Res. Cardiol. 107, 30\u201341 (2018).","journal-title":"Clin. Res. Cardiol."},{"key":"2190_CR23","doi-asserted-by":"publisher","first-page":"23.16.1","DOI":"10.1002\/cpmb.9","volume":"115","author":"H Wakimoto","year":"2016","unstructured":"Wakimoto, H., Seidman, J. G., Foo, R. S. & Jiang, J. AAV9 delivery of shRNA to the mouse heart. Curr. Protoc. Mol. Biol. 115, 23.16.1\u201323.16.9 (2016).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"2190_CR24","doi-asserted-by":"publisher","first-page":"e2204174119","DOI":"10.1073\/pnas.2204174119","volume":"119","author":"A Axelsson Raja","year":"2022","unstructured":"Axelsson Raja, A. et al. Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model. Proc. Natl Acad. Sci. USA 119, e2204174119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2190_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12968-021-00720-9","volume":"23","author":"CE Raphael","year":"2021","unstructured":"Raphael, C. E. et al. Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation. J. Cardiovasc. Magn. Reson. 23, 26 (2021).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"2190_CR26","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.hlc.2021.04.008","volume":"30","author":"S Vullaganti","year":"2021","unstructured":"Vullaganti, S. et al. Fibrosis in hypertrophic cardiomyopathy patients with and without sarcomere gene mutations. Heart Lung Circ. 30, 1496\u20131501 (2021).","journal-title":"Heart Lung Circ."},{"key":"2190_CR27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080 (2008).","journal-title":"Mol. Ther."},{"key":"2190_CR28","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.echo.2015.07.015","volume":"28","author":"M Ro\u015fca","year":"2015","unstructured":"Ro\u015fca, M. et al. Right ventricular remodeling, its correlates, and its clinical impact in hypertrophic cardiomyopathy. J. Am. Soc. Echocardiogr. 28, 1329\u20131338 (2015).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"2190_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91892-y","volume":"11","author":"S Nedios","year":"2021","unstructured":"Nedios, S. et al. Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy. Sci. Rep. 11, 12411 (2021).","journal-title":"Sci. Rep."},{"key":"2190_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/pr.2015.109","volume":"78","author":"DS Tai","year":"2015","unstructured":"Tai, D. S., Hu, C., Kim, E. H. & Lipshutz, G. S. Augmentation of transgene-encoded protein after neonatal injection of adeno-associated virus improves hepatic copy number without immune responses. Pediatr. Res. 78, 239\u2013246 (2015).","journal-title":"Pediatr. Res."},{"key":"2190_CR31","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1172\/JCI70108","volume":"124","author":"DC Christodoulou","year":"2014","unstructured":"Christodoulou, D. C. et al. 5\u2032RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J. Clin. Invest. 124, 1364\u20131370 (2014).","journal-title":"J. Clin. Invest."},{"key":"2190_CR32","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41596-018-0055-0","volume":"13","author":"CR Lazzarotto","year":"2018","unstructured":"Lazzarotto, C. R. et al. Defining CRISPR\u2013Cas9 genome-wide nuclease activities with CIRCLE-seq. Nat. Protoc. 13, 2615\u20132642 (2018).","journal-title":"Nat. Protoc."},{"key":"2190_CR33","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","volume":"39","author":"T Rothgangl","year":"2021","unstructured":"Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949\u2013957 (2021).","journal-title":"Nat. Biotechnol."},{"key":"2190_CR34","doi-asserted-by":"crossref","unstructured":"Davis, J. R. et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat. Biomed. Eng. 6, 1272\u20131283 (2022).","DOI":"10.1038\/s41551-022-00911-4"},{"key":"2190_CR35","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1172\/JCI118992","volume":"98","author":"WK Jones","year":"1996","unstructured":"Jones, W. K. et al. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J. Clin. Invest. 98, 1906\u20131917 (1996).","journal-title":"J. Clin. Invest."},{"key":"2190_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI4631","volume":"103","author":"D Fatkin","year":"1999","unstructured":"Fatkin, D. et al. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the \u03b1 cardiac myosin heavy chain gene. J. Clin. Invest. 103, 147\u2013153 (1999).","journal-title":"J. Clin. Invest."},{"key":"2190_CR37","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/0002-8703(83)90701-9","volume":"106","author":"WA Neill","year":"1983","unstructured":"Neill, W. A., Sewell, D. H., Gosalia, K. P., Kingsley, E. M. & Oxendine, J. M. Atrial coronary hyperemia and ischemia in response to variations in atrial pressure in dogs. Am. Heart J. 106, 554\u2013558 (1983).","journal-title":"Am. Heart J."},{"key":"2190_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.hrthm.2015.01.016","volume":"12","author":"KA van Bragt","year":"2015","unstructured":"van Bragt, K. A. et al. Dynamic regulation of atrial coronary blood flow in healthy adult pigs. Heart Rhythm 12, 991\u20131000 (2015).","journal-title":"Heart Rhythm"},{"key":"2190_CR39","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/humu.24309","volume":"43","author":"S Gudmundsson","year":"2022","unstructured":"Gudmundsson, S. et al. Variant interpretation using population databases: lessons from gnomAD. Hum. Mutat. 43, 1012\u20131030 (2022).","journal-title":"Hum. Mutat."},{"key":"2190_CR40","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2190_CR41","doi-asserted-by":"publisher","first-page":"eaax5717","DOI":"10.1126\/sciadv.aax5717","volume":"5","author":"HA Rees","year":"2019","unstructured":"Rees, H. A., Wilson, C., Doman, J. L. & Liu, D. R. Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci. Adv. 5, eaax5717 (2019).","journal-title":"Sci. Adv."},{"key":"2190_CR42","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"2190_CR43","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","volume":"38","author":"NM Gaudelli","year":"2020","unstructured":"Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892\u2013900 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2190_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"2190_CR45","doi-asserted-by":"publisher","first-page":"10576","DOI":"10.1093\/nar\/gkaa764","volume":"48","author":"DY Kim","year":"2020","unstructured":"Kim, D. Y., Moon, S. B., Ko, J.-H., Kim, Y.-S. & Kim, D. Unbiased investigation of specificities of prime editing systems in human cells. Nucleic Acids Res. 48, 10576\u201310589 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2190_CR46","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1136\/heartjnl-2016-310015","volume":"102","author":"CY Ho","year":"2016","unstructured":"Ho, C. Y. et al. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart 102, 1805\u20131812 (2016).","journal-title":"Heart"},{"key":"2190_CR47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1089\/hum.2010.055","volume":"21","author":"M Lock","year":"2010","unstructured":"Lock, M. et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene Ther. 21, 1259\u20131271 (2010).","journal-title":"Hum. Gene Ther."},{"key":"2190_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-4939-9139-6_4","volume":"1950","author":"J Sanmiguel","year":"2019","unstructured":"Sanmiguel, J., Gao, G. & Vandenberghe, L. H. Quantitative and digital droplet-based AAV genome titration. Methods Mol. Biol. 1950, 51\u201383 (2019).","journal-title":"Methods Mol. Biol."},{"key":"2190_CR49","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"2190_CR50","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"2190_CR51","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","volume":"14","author":"SQ Tsai","year":"2017","unstructured":"Tsai, S. Q. et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR\u2013Cas9 nuclease off-targets. Nat. Methods 14, 607\u2013614 (2017).","journal-title":"Nat. Methods"},{"key":"2190_CR52","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","volume":"588","author":"M Litvi\u0148ukov\u00e1","year":"2020","unstructured":"Litvi\u0148ukov\u00e1, M. et al. Cells of the adult human heart. Nature 588, 466\u2013472 (2020).","journal-title":"Nature"},{"key":"2190_CR53","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"2190_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cels.2020.05.010","volume":"11","author":"NJ Bernstein","year":"2020","unstructured":"Bernstein, N. J. et al. Solo: doublet identification in single-cell RNA-seq via semi-supervised deep learning. Cell Syst. 11, 95\u2013101.e5 (2020).","journal-title":"Cell Syst."},{"key":"2190_CR55","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/bib\/bbx129","volume":"20","author":"MA Diroma","year":"2019","unstructured":"Diroma, M. A., Ciaccia, L., Pesole, G. & Picardi, E. Elucidating the editome: bioinformatics approaches for RNA editing detection. Brief. Bioinform. 20, 436\u2013447 (2019).","journal-title":"Brief. Bioinform."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02190-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T14:05:55Z","timestamp":1677765955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02190-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02190-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.H.V. holds equity and serves on the Board of Directors for Affinia Therapeutics and Ciendias Bio, where he is employed, and holds equity in Akouos. He has licensed technology to Affinia, Akouos and Novartis. D.R.L. is a consultant and equity owner of Beam Therapeutics, Prime Medicine, Pairwise Plants and Chroma Medicine, companies that use genome editing or genome engineering. J.G.S. and C.E.S are founders of Myokardia (a Bristol Myers Squibb subsidiary) and are consultants for Maze and BridgeBio. C.E.S serves on the Merck Board of Directors and the Burroughs Wellcome Fund. None of these companies had any input into the design, execution, analyses or writing of this manuscript. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}